International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2026
Incidence and clinical features of cataracts: an under-recognized adverse event with mirvetuximab soravtansine-gynx in ovarian cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Flint Matthew L, Shvygin Anna, Johannet Paul, Cohen Seth, Konner Jason, Tew William P, Grisham Rachel N, Francis Jasmine H, Canestraro Julia, O'Cearbhaill Roisin E
Аннотация
OBJECTIVE: To characterize the incidence and clinical features of cataracts in patients with folate receptor α-positive recurrent high-grade serous ovarian cancer treated with mirvetuximab soravtansine-gynx, an antibody-drug conjugate targeting folate receptor 1.
METHODS: We conducted a single-center retrospective cohort study in patients treated with mirvetuximab soravtansine-gynx between February 2023 and January 2025. All patients underwent baseline and serial ophthalmologic assessments, and received prophylactic ophthalmic corticosteroids as required by mirvetuximab soravtansine-gynx US Prescribing Information. Cataracts were graded according to the Lens Opacities Classification System III.
RESULTS: A total of 108 patients were identified. Median age at mirvetuximab soravtansine-gynx initiation was 65 years (range; 37-84). Of 108 patients, 73 (67.6%) had cataracts at baseline and/or during follow-up. Among 49 patients without baseline cataracts, new cataracts developed in 14 (28.6%). Among 40 patients (excluding an additional 18 with bilateral pseudophakia and 1 with bilateral aphakia) with baseline cataracts, 9 (22.5%) indicated cataract progression. Nuclear sclerosis was the predominate cataract sub-type (20/23). Patients with new/progressive cataracts received more mirvetuximab soravtansine-gynx cycles (median, 8 vs 5) than those who did not. Non-cataract ocular toxicity rates were similar across groups.
CONCLUSIONS: Cataracts represent an under-recognized ocular adverse event associated with mirvetuximab soravtansine-gynx treatment. Although the etiology remains unclear, potentially related to mirvetuximab soravtansine-gynx exposure, ocular corticosteroids, or both, the frequency and tempo observed in this cohort underscore the need for close ophthalmologic monitoring. However, it is reassuring that cataracts can be treated with a minimally invasive procedure with generally excellent outcomes. Further research is warranted to elucidate underlying mechanisms and optimize supportive eye care strategies.
METHODS: We conducted a single-center retrospective cohort study in patients treated with mirvetuximab soravtansine-gynx between February 2023 and January 2025. All patients underwent baseline and serial ophthalmologic assessments, and received prophylactic ophthalmic corticosteroids as required by mirvetuximab soravtansine-gynx US Prescribing Information. Cataracts were graded according to the Lens Opacities Classification System III.
RESULTS: A total of 108 patients were identified. Median age at mirvetuximab soravtansine-gynx initiation was 65 years (range; 37-84). Of 108 patients, 73 (67.6%) had cataracts at baseline and/or during follow-up. Among 49 patients without baseline cataracts, new cataracts developed in 14 (28.6%). Among 40 patients (excluding an additional 18 with bilateral pseudophakia and 1 with bilateral aphakia) with baseline cataracts, 9 (22.5%) indicated cataract progression. Nuclear sclerosis was the predominate cataract sub-type (20/23). Patients with new/progressive cataracts received more mirvetuximab soravtansine-gynx cycles (median, 8 vs 5) than those who did not. Non-cataract ocular toxicity rates were similar across groups.
CONCLUSIONS: Cataracts represent an under-recognized ocular adverse event associated with mirvetuximab soravtansine-gynx treatment. Although the etiology remains unclear, potentially related to mirvetuximab soravtansine-gynx exposure, ocular corticosteroids, or both, the frequency and tempo observed in this cohort underscore the need for close ophthalmologic monitoring. However, it is reassuring that cataracts can be treated with a minimally invasive procedure with generally excellent outcomes. Further research is warranted to elucidate underlying mechanisms and optimize supportive eye care strategies.